What's at stake: Medicinal cannabis players want the sector's stringent regulations eased following the collapse of several companies, with investors losing millions of dollars. Others see a bright future for the survivors and new entrants in the industry, with exports and the domestic market growing.
Background: Helius Therapeutics is the latest medicinal cannabis company to go into voluntary administration due to high costs and regulatory constraints. The voluntary administrators have delayed a crucial watershed meeting for three months while they attempt to sell the business assets to interested parties.
Key players: Helius, Puro, Ora Pharm, Nubu, CannaPlus, Cannabis Clinic, Medsafe, Minister for Regulation, Medicinal Cannabis Agency, NZ Medicinal Cannabis Council.
Standing in the sunshine amidst Puro’s six-foot-high cannabis plants on the Kaikoura coast just before harvest, it’s easy to share the Pollyanna-ish view of some that New Zealand’s medicinal cannabis industry has a bright future.
For the record, Shoeshine didn’t partake of any of the
Sign up to get the latest stories and insights delivered to your inbox – free, every day.
Key points
What's at stake: Medicinal cannabis players want the sector's stringent regulations eased following the collapse of several companies, with investors losing millions of dollars. Others see a bright future for the survivors and new entrants in the industry, with exports and the domestic market growing.
Background: Helius Therapeutics is the latest medicinal cannabis company to go into voluntary administration due to high costs and regulatory constraints. The voluntary administrators have delayed a crucial watershed meeting for three months while they attempt to sell the business assets to interested parties.
Key players: Helius, Puro, Ora Pharm, Nubu, CannaPlus, Cannabis Clinic, Medsafe, Minister for Regulation, Medicinal Cannabis Agency, NZ Medicinal Cannabis Council.
